Supernus Pharmaceuticals (SUPN) Net Income towards Common Stockholders (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$4.1 million in Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 126.78% year-over-year to -$4.1 million in Q4 2025; TTM through Mar 2026 was -$26.7 million, a 143.14% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 152.19% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$4.1 million, up from -$45.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for SUPN reached as high as $38.5 million in Q3 2024 and fell as low as -$45.1 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged $7.5 million across 5 years, with a median of $6.8 million in 2021.
• Across the five-year window, Net Income towards Common Stockholders jumped 2506.53% in 2024 and slumped 8370.63% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $2.4 million in 2021, then surged by 944.55% to $25.5 million in 2022, then sank by 95.39% to $1.2 million in 2023, then soared by 1204.51% to $15.3 million in 2024, then sank by 126.78% to -$4.1 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$4.1 million in Q4 2025, -$45.1 million in Q3 2025, and $22.5 million in Q2 2025.